ALNY
Alnylam Pharmaceuticals, Inc.Company with tickers: ALNY
CIK
1178670
CUSIP
02043Q107
Shares Outstanding
133,512,573
Website
https://www.alnylam.com
Investor Relations
https://investors.alnylam.com/
13F Activity (30d)
32 filings
24 filers
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Benjamin F. Cravatt, Ph.D. | Class III director | Appointed | 2026-05-27 |